TRANSDERMAL DRUG DELIVERY DEVICES - GLOBAL MARKETS

79 Pages | 27 Exhibits | 2017 Analysis | Forecasts Through 2021

OVERVIEW:
This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the market for transdermal patches intended for the management of CVD, neurologic disorders, HRT, pain, and genitourinary disorders.

TRANSDERMAL DRUG DELIVERY DEVICES MARKET HIGHLIGHTS

  • The increasing prevalence of CVD, neurological disorders, menopause, chronic pain, overactive bladder, and hypogonadism are increasing as the population ages, creating opportunities for treatments including transdermal drug therapies.
  • The combined global market for transdermal drug delivery products totaled nearly $7bn in 2016, and is expected to climb at a rate of nearly 3% over the forecast period.
  • The pain management segment accounts for half the overall market ($3.5bn in 2016); the neurological disorders management segment is expected to experience the greatest growth over the forecast period (3.6%).
  • In the neurological disorder management segment, factors contributing to growth include the increasing prevalence of disorders such as Alzheimer's and Parkinson's diseases with the aging of the population, as well as increased compliance offered by transdermal technology compared to oral medications, particularly in patients with memory issues related to their disease.
Key Questions Answered
  • What are the key drivers and limiters to the transdermal drug delivery devices market?
  • Which competitors are leading the market and introducing new technology?
  • How are technological advancements impacting market growth?
  • Which areas of the transdermal drug delivery devices market are experiencing dynamic growth?
  • How are mergers and acquisitions affecting the markets shares of leading competitors?


  • TABLE OF CONTENTS:
    Executive Summary
    
    i. Transdermal drug delivery devices market
    	a. Selected market drivers and limiters 
    	b. CVD segment
    	c. Neurological disorder segment
    	d. HRT segment 
    	e. Pain management segment
    	f. Genitourinary disorder segment 
    	g. Market leaders
    	h. Emerging competition
    ii. Methodology
    
    Exhibit ES-1: Transdermal drug delivery devices market forecast, by segment ($m), 2016-21 
    Exhibit ES-2: Transdermal drug delivery devices market forecast, by region ($m), 2016-21 
    
    1. Transdermal Drug Delivery Technology
     
    1.1 Technology
    	1.1.1 Passive transdermal transport systems
    	1.1.2 Active transdermal transport systems 
    1.2 Clinical applications
    1.3 Bibliography
    
    2. Transdermal Drug Delivery Systems
    
    2.1 Cardiovascular disease management 
    	2.1.1 Angina pectoris
    	2.1.2 Hypertension 
    	2.1.3 Products 
    	2.1.4 Emerging products 
    	2.1.5 Market analysis 
    	2.1.6 Competitive analysis 
    2.2 Neurological disorder management
    	2.2.1 Attention deficit hyperactivity disorder 
    	2.2.2 Alzheimer's disease 
    	2.2.3 Major depressive disorder 
    	2.2.4 Parkinson's disease 
    	2.2.5 Products 
    	2.2.6 Emerging products 
    	2.2.7 Market analysis 
    	2.2.8 Competitive analysis 
    2.3 Hormone replacement therapy 
    	2.3.1 Menopause
    	2.3.2 Osteoporosis 
    	2.3.3 Products 
    	2.3.4 Emerging products 
    	2.3.5 Market analysis 
    	2.3.6 Competitive analysis 
    2.4 Pain management 
    	2.4.1 Cancer-related pain
    	2.4.2 Postherpetic neuralgia
    	2.4.3 Products 
    	2.4.4 Market analysis 
    	2.4.5 Competitive analysis 
    2.5 Genitourinary disorder management 
    	2.5.1 Overactive bladder 
    	2.5.2 Hypogonadism 
    	2.5.3 Products 
    	2.5.4 Market analysis 
    2.6 Bibliography
    
    Exhibit 2-1: Patch-based pharmaceutical products, by application, combined market forecast ($m), 2016-21
    Exhibit 2-2: Age-standardized incidence of angina pectoris per 100,000 population, selected regions, 1990 and 2010 
    Exhibit 2-3: Estimated prevalence of hypertension, selected countries
    Exhibit 2-4: Mortality attributable to hypertensive diseases, selected countries 
    Exhibit 2-5: Selected patch-based clonidine and nitroglycerin products, 2017
    Exhibit 2-6: Patch-based clonidine and nitroglycerin products, market forecast, by country/region ($m), 2016-21
    Exhibit 2-7: Patch-based clonidine and nitroglycerin products, market share by supplier, 2016 
    Exhibit 2-8: Estimated prevalence of selected neurological conditions (millions), US and worldwide 
    Exhibit 2-9: Selected patch-based neurological disorder treatment products, 2017
    Exhibit 2-10: Patch-based neurological disorder treatment products, market forecast, by country/region ($m), 2016-21
    Exhibit 2-11: Patch-based neurological disorder treatment products, market share by supplier, 2016 
    Exhibit 2-12: Estimated prevalence of osteoporosis, selected countries 
    Exhibit 2-13: Selected patch-based hormone replacement products, 2017 
    Exhibit 2-14: Patch-based estrogen replacement products, market forecast, by country/region ($m), 2016-21 
    Exhibit 2-15: Patch-based estrogen replacement products, market share by supplier, 2016 
    Exhibit 2-16: Estimated prevalence of pain, selected countries 
    Exhibit 2-17: Age-standardized cancer incidence and mortality, selected countries, 2012
    Exhibit 2-18: WHO analgesic ladder
    Exhibit 2-19: Selected patch-based pain management products, 2017
    Exhibit 2-20: Patch-based pain management products, market forecast, by country/region ($m) 2016-21 
    Exhibit 2-21: Patch-based pain management products, market share by supplier, 2016 
    Exhibit 2-22: Estimated prevalence of overactive bladder, by gender, US and EU 
    Exhibit 2-23: Estimated prevalence of hypogonadism, US and EU
    Exhibit 2-24: Selected patch-based genitourinary disorder treatment products, 2017
    Exhibit 2-25: Patch-based genitourinary treatment products, market forecast, by product ($m), 2016-21
    
    Appendix: Company Listing 
    


    COMPANIES COVERED:

    1. 3M Health Care/3M Company
    2. Acrux LTD
    3. ActivaTek, Inc.
    4. Allergan, Inc.
    5. AngioSoma, Inc.
    6. Antares Pharma, Inc.
    7. Apotex Corporation
    8. Apricus Biosciences, Inc.
    9. Bayer HealthCare/Bayer AG
    10. Boehringer Ingelheim GmbH
    11. Corium International, Inc.
    12. DJO Global LLC
    13. Fennec Pharmaceuticals
    14. Heron Therapeutics, Inc.
    15. Janssen Pharmaceuticals NV/Johnson & Johnson
    16. Mayne Pharma LTD
    17. The Medicines Company
    18. Merck & Co, Inc.
    19. Micron Biomedical, Inc.
    20. Mylan Technologies, Inc.
    21. MyLife Technologies
    22. Nemaura Medical, Inc.
    23. Novartis AG
    24. Noven Pharamceuticals, Inc./Hisamitsu Pharmaceutical Co., Inc.
    25. Purdue University
    26. Sandoz International GmbH/Novartis AG
    27. SkinJect, Inc.
    28. Teikoku Pharma USA/Teikoku Seiyaku Co., LTD
    29. Teva Pharmaceutical Industries LTD
    30. TheraJect, Inc.
    31. Toa Eiyo LTD
    32. Travanti Medical, Inc.
    33. UCB Group
    34. Valeant Pharmaceuticals International
    35. Valeritas, Inc.
    36. Vaxxas Pty LTD
    37. Zosano Pharma Corporation
Contact Us

Need help finding medtech research? Let us help you!